Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

Cambridge, MA - August 6, 2019

Read the original article here